Gunther Staffler
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Corrigendum to "Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease" [Neurobiology of Disease, 2024 Jan:190:106376].
Journal: Neurobiology of disease
Published: February 24, 2024
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
Journal: Journal of Parkinson's disease
Published: June 07, 2021
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
Journal: European journal of clinical pharmacology
Published: March 09, 2021
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: March 27, 2020
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance.
Journal: Translational neurodegeneration
Published: March 24, 2020
Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease.
Journal: Neurobiology of disease
Published: December 20, 2019
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
Journal: The Lancet. Neurology
Published: December 13, 2019
NMR Characterization of Surface Receptor Protein Interactions in Live Cells Using Methylcellulose Hydrogels.
Journal: Angewandte Chemie (International ed. in English)
Published: October 24, 2019
Antibody-mediated targeting of cleavage-specific OPN-T cell interactions.
Journal: PloS one
Published: August 27, 2018
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Journal: European heart journal
Published: October 18, 2016
Osteopontin is a key player for local adipose tissue macrophage proliferation in obesity.
Journal: Molecular metabolism
Published: August 16, 2016
Last Updated: 09/26/2026